20 February 2018

World leaders in their fields

Accelera is among the 'World leaders' collaborating with the publicly listed biotechnology company Aptahem for lead candidate Apta-1.

Based in Malmö, Sweden, Aptahem develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved.
Our Accelera team is performing the non-clinical toxicology program to drive the development of lead candidate Apta-1 in the most cost-effective manner, meeting all the GLP requirements.
More info on http://aptahem.com/en/development-partners